Ph1 TSCAN-001 Trial Shows Encouraging Preliminary Results; TScan to Initiate Trial in Solid Tumors in 2023; 8 IND Submissions Expected by YE 2024; Kelonia Presents Promising In Vivo CAR-T Preclinical Results; ASCGT 2023 Analysis 1
ASGCT 2023 Analysis 1: Tscan presented preliminary clinical data of the Ph1 TSCAN-001 trial while Kelonia presented preclinical results of its innovative in vivo CAR-T platform. Moreover, on May 17, TScan held a virtual ASGCT meeting further detailing their initial clinical results. Below, Celltelligence provides insights and context for key selected presentations. The following topics are covered:
About The Author
The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.
If you receive our email blasts, you already have an account. Log in now
You’ll be able to access the full article from your Celltelligence Library after signing up.